AB Corporate Bond ETF (NASDAQ:EYEG) Share Price Crosses Below 50 Day Moving Average – Here’s Why

AB Corporate Bond ETF (NASDAQ:EYEG)’s share price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $35.25 and traded as low as $35.17. AB Corporate Bond ETF shares last traded at $35.23, with a volume of 1,267 shares traded.

AB Corporate Bond ETF Trading Down 0.6%

The company has a market cap of $28.18 million, a P/E ratio of -20.97 and a beta of 0.18. The stock’s 50 day moving average is $35.25 and its 200-day moving average is $35.64. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

AB Corporate Bond ETF Increases Dividend

The business also recently announced a monthly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Monday, June 1st will be paid a dividend of $0.1415 per share. The ex-dividend date is Monday, June 1st. This represents a c) annualized dividend and a yield of 4.8%. This is an increase from AB Corporate Bond ETF’s previous monthly dividend of $0.14. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -103.57%.

Hedge Funds Weigh In On AB Corporate Bond ETF

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in AB Corporate Bond ETF during the 4th quarter valued at about $34,000. Jane Street Group LLC purchased a new stake in shares of AB Corporate Bond ETF during the 2nd quarter valued at about $232,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of AB Corporate Bond ETF by 32.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock valued at $5,634,000 after purchasing an additional 38,685 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.